Cargando…
Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338281/ https://www.ncbi.nlm.nih.gov/pubmed/28286614 |
_version_ | 1782512522547429376 |
---|---|
author | Payandeh, Mehrdad Sadeghi, Masoud Sadeghi, Edris Janbakhsh, Alireza |
author_facet | Payandeh, Mehrdad Sadeghi, Masoud Sadeghi, Edris Janbakhsh, Alireza |
author_sort | Payandeh, Mehrdad |
collection | PubMed |
description | Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusion: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+. |
format | Online Article Text |
id | pubmed-5338281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-53382812017-03-10 Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? Payandeh, Mehrdad Sadeghi, Masoud Sadeghi, Edris Janbakhsh, Alireza Int J Hematol Oncol Stem Cell Res Original Article Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusion: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2017-01-01 /pmc/articles/PMC5338281/ /pubmed/28286614 Text en Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Payandeh, Mehrdad Sadeghi, Masoud Sadeghi, Edris Janbakhsh, Alireza Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title | Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_full | Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_fullStr | Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_full_unstemmed | Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_short | Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_sort | is there any concordance between of ihc with fish in her2-positive breast cancer patients? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338281/ https://www.ncbi.nlm.nih.gov/pubmed/28286614 |
work_keys_str_mv | AT payandehmehrdad isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients AT sadeghimasoud isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients AT sadeghiedris isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients AT janbakhshalireza isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients |